A randomized phase 2 study comparing different dose-approaches of induction treatment (first cycle) of regorafenib in metastatic colorectal cancer (mCRC) patients
Ontology highlight
ABSTRACT: Primary objectives: To evaluate the safety and tolerability of different dose-escalation approaches of regorafenib in mCRC patients.
Primary endpoints: Percentage of patients with G3/G4 treatment-related AEs in each arm according to CTCAE v4.03 criteria.
DISEASE(S): Metastatic Colorectal Cancer,Cancer Colorectal Metastásico
PROVIDER: 2535505 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA